Mason RJ, Buist AS, Fisher EB, Merchant JA, Samet JM, Welsh CH. Cigarette smoking and health. Am Rev Respir Dis. 1985;132:1133–1136.PubMed
Centers for Disease Control and Prevention. Sample adult core component of the 1997-2006 National Health Interview Survey. Available at: http://www.cdc.gov/nchs/data/hus/hus08pdf#063
. Accessed March 4, 2009.
American Thoracic Society. Cigarette smoking and health. Am J Respir Crit Care Med. 1996;153:861–865.
Ezatti M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet. 2003;362:847–852.CrossRef
Centers for Disease Control and Prevention (CDC). Tobacco use — United States, 1900–1999. MMWR Morb Mortal Wkly Rep. 1999;48:986–993.
Centers for Disease Control and Prevention (CDC). Annual smoking attributable mortality, years of potential life lost, and economic costs - United States, 1995-1999. MMWR Morb Mortal Wkly Rep. 2002;51:300–303.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66.PubMedCrossRef
Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS. Smoking cessation in mild to moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med. 2000;161:381–390.PubMed
Department of Health and Human Services. The health consequences of smoking: a report of the Surgeon General. Atlanta, GA: National Center of Chronic Disease Prevention and Health Promotion; 2004.
Ezzati M, Henley SJ, Thun MJ, Lopez AD. Role of smoking in global and regional cardiovascular mortality. Circulation. 2005;112:489–497.PubMedCrossRef
Godtfredsen NS, Holst C, Prescott E, et al. Smoking reduction, smoking cessation, and mortality: a 16 year follow up of 19,732 men and women from the Copenhagen centre for prospective population studies. Am J Epidemiol. 2002;156:994–1001.PubMedCrossRef
Samet JM. The health benefits of smoking cessation. Med Clin North Am. 1992;76:399–414.PubMed
Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of inhaled anticholinergic bronchodilators on the rate of decline of FEV1. JAMA. 1994;272:1497–1505.PubMedCrossRef
US Department of Health and Human Services. The health benefits of smoking cessation. A report of the Surgeon General, 1990. DHHS Publication No. (CDC) 90-8416. Rockville, MD: US Public Health Services, Office on Smoking and Health; 1990.
Taylor DH Jr, Hassalblad V, Henley SJ, Thun MJ, Sloan FA. Benefits of smoking cessation for longevity. Am J Public Health. 2002;92:990–996.PubMedCrossRef
Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. A clinical practice guideline for treating tobacco use and dependence: a US Public Health Service report. JAMA. 2000;283:3244–3254.CrossRef
Anderson JE, Jorenby DE, Scott WJ, Fiore MC. Treating tobacco use and dependence: an evidencebased clinical practice guideline for tobacco cessation. Chest. 2002;121:932–941.PubMedCrossRef
Rigotti NA. Treatment of tobacco use and dependence. N Engl J Med. 2002;346:506–512.PubMedCrossRef
US Preventive Services Task Force. Counseling to prevent tobacco use and tobacco-caused disease: recommendation statement. Rockville, MD: Agency for Healthcare Research and Quality; 2003.
Office of the US Surgeon General. The health consequences of smoking: nicotine addiction: a report of the Surgeon General. DHHS Publication No. (CDC) 88-8406. Atlanta, GA: Centers for Health Promotion and Education, Office on Smoking and Health; 1988.
Henningfield JE, Stapelton JM, Benowitz NI, Grayson RF, London ED. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend. 1993;33:23–29.PubMedCrossRef
Watkins SS, Koob GF, Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res. 2000;2:19–37.PubMedCrossRef
Hughes JR. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res. 2007;9:315–327.PubMedCrossRef
Fiore MC, Jaen CR, Baker TB, et al. Clinical practice guideline: treating tobacco use and dependence 2008 update. Rockville, MD: Department of Health and Human Services; 2008.
Okuyeni KS, Ahluwalia JS, Harris KJ. Pharmacotherapy of smoking cessation. Arch Fam Med. 2000;9:270–281.CrossRef
Molyneux A. Nicotine replacement therapy. BMJ. 2004;328:454–456.PubMedCrossRef
Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;(3):CD000146.
Lam W, Sze PC, Sacks HS, Chalmers TC. Metaanalysis of randomised controlled trials of nicotine chewing-gum. Lancet. 1987;2:27–30.PubMedCrossRef
Schneider NG, Lunell E, Olmstead RE, Fagerström KO. Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems. Clin Pharmacokinet. 1996;31:65–80.PubMedCrossRef
Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA. 1994;271:1940–1947.PubMedCrossRef
Schneider NG, Olmstead R, Mody FV, et al. Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction. 1995;90:1671–1682.PubMedCrossRef
Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2008;(1):CD000146.
Hajek R, West R, Foulds J, Nilsson F, Burrows S, Meadow A. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med. 2000;159;2033–2038.CrossRef
Bohadana A, Nilsson F, Rasmussen T, Martinet Y. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo controlled trial. Arch Intern Med. 2000;160:3128–3134.PubMedCrossRef
Benowitz NL, Steven GG. Cardiovascular toxicity of nicotine: implication for nicotine replacement therapy. J Am Coll Cardiol. 1997;7:1422–1437.CrossRef
Dempsey DA, Benowitz NL. Risks and benefits of nicotine to aid smoking cessation in pregnancy. Drug Saf. 2001;24:277–322.PubMedCrossRef
Coleman T, Britton J, Thornton J. Nicotine replacement therapy in pregnancy. BMJ. 2004;328;965–966.PubMedCrossRef
Rose JE. Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology (Berl). 2006;184:274–285.CrossRef
Balfour DJ. The pharmacology underlying pharmacotherapy for tobacco dependence: a focus on bupropion. Int J Clin Pract. 2001;55:53–57.PubMed
Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007;(1):CD000031.
Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995;56:395–401.PubMed
Cryan JF, Dalvi A, Jin SH, Hirsch BR, Lucki I, Thomas SA. Use of dopamine-beta-hydroxylase-deficient mice to determine the role of norepinephrine in the mechanism of action of antidepressant drugs. J Pharmacol Exp Ther. 2001;298:651–657.PubMed
Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology. 2002;163:102–105.PubMedCrossRef
Semmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther. 2000;295:321–327.
Hurt RD, Sachs DPL, Glover ED, et al. A comparison of slow release buproprion and placebo for smoking cessation. N Engl J Med. 1997;337:1195–1202.PubMedCrossRef
Swan GE, McAfee T, Curry SJ, et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Arch Intern Med. 2003;163:2337–2344.PubMedCrossRef
Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685–691.PubMedCrossRef
Fiore MC, Bailey WC, Cohen SJ et al. Treating tobacco use and dependence. Rockville, MD: Department of Health and Human Services, Public Health Service; 2000.
Wilkes S. The use of bupropion SR in cigarette smoking cessation. Int J Chron Ostruct Pulmon Dis. 2008;3:45–53.
Slater YE, Houlihan LM, Maskell PD et al. Halogenated cytosine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes. Neuropharmacology. 2003;44:503–515.PubMedCrossRef
Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48:3474–3477.PubMedCrossRef
Aveyard P, West R. Managing smoking cessation. BMJ. 2007;335:37–41.PubMedCrossRef
Jorenby DE, Hays JT, Rigotti NA, et al. Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56–63.PubMedCrossRef
Tonstad S, Tonnensen P, Hajek P, Williams KE, Billing CB, Reeves KR. Varenicline Phase 3 Study Group. Effects of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296:64–71.PubMedCrossRef
Gonzales D, Rennard SI, Nides M, et al. Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist vs sustained release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47–55.PubMedCrossRef
Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ. 2008;179:135–144.PubMed
Stapleton JA, Watson L, Spirling LI, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction. 2008;103:146–154.PubMedCrossRef
Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax. 2008;63:717–724.PubMedCrossRef
Hays JT, Ebbert JO. Varenicline for tobacco dependence. N Engl J Med. 2008;359:2018–2024.PubMedCrossRef
US Drug and Food Administration, Center for Drug Evaluation and Research. Varenicline [marketed as Chantix] information. Washington, DC: US Department of Health and Human Services; 2008.
Obach RS, Reed-Hagen AE, Krueger SS, et al. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos. 2006;34:121–130.PubMedCrossRef
Etter JF. Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Intern Med. 2006;166:1553–1559.PubMedCrossRef
Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev. 2004;(3):CD000058.
Johnson BA, Ait-Daoud N, Akhtar FZ, Javors MA. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Arch Intern Med. 2005;165:1600–1605.PubMedCrossRef
George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O’Malley SS. A preliminary placebocontrolled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry. 2003;53:136–143.PubMedCrossRef
Jarvik ME, Caskey NH, Wirshing WC, et al. Bromocriptine reduces cigarette smoking. Addiction. 2000;95:1173–1183.PubMedCrossRef
Cahill K, Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev. 2007;(4):CD005353.
Cryan JF, Gasparini F, van Heeke G, Markou A. Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropion. Drug Discov Today. 2003;8:1025–1034.PubMedCrossRef
Cornuz J, Zwahlen S, Jungi WF, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS ONE. 2008;3:e2547.PubMedCrossRef
Law M, Tang JL. An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med. 1995;155:1933–1941.PubMedCrossRef
Rigotti NA, Munafo MR, Stead LF. Smoking cessation interventions for hospitalized smokers: a systematic review. Arch Intern Med. 2008;168:1950–1960.PubMedCrossRef
Stratelis G, Mölstad S, Jakobsson P, Zetterström O. The impact of repeated spirometry and smoking cessation advice on smokers with mild COPD. Scand J Prim Health Care. 2006;24:133–139.PubMedCrossRef
Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years observation on male British doctors. BMJ. 2004;328:1519.PubMedCrossRef